Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has opened its non-renounceable pro rata entitlement offer to eligible shareholders, making the prospectus and personalised entitlement and acceptance forms available from today.
The company said eligible shareholders have until 5:00pm AEST on Wednesday, April 8, 2026, to take up their entitlement in full or in part under the offer.
Gold prices are showing increased volatility, prompting renewed investor focus on cost discipline and margin resilience across the mining sector, according to analysts at Jefferies.
The price of gold fell more than 3% to trade just abot $4,400 per ounce on Monday.
Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) announced that it will open its first US brain-dedicated positron emission tomography (PET) scanning clinic at the HCA Florida University Medical Office Building in Davie, on the campus of HCA Florida University Hospital.
The company, through its wholly owned subsidiary Algernon USA LLC, has signed a five-year lease for the site with an option to renew for an additional five years. It said the Davie location will serve as its flagship clinic, with plans to establish multiple sites across the United States.
Graphene Manufacturing Group Ltd (TSX-V:GMG, OTCQX:GMGMF) said it has launched its European sales operations and strengthened its intellectual property position, as the company looks to expand its commercial footprint in the region.
The Canada-based company said it held a kickoff training workshop in London during the week of March 9, bringing together newly hired sales personnel from across Europe and the UK for technical and commercial training.
Shares inZenith Energy Ltd (LSE:ZEN, TSX-V:ZEE), the international energy producer listed in London, Oslo and Stockholm, rose 7% to 7.5p after the company announced that construction of a 7 megawatt-peak (MWp) solar portfolio in the Puglia region of southern Italy will begin in July 2026.
The project, comprising three solar plants, is fully financed, with external debt covering 85% of total costs and Zenith contributing approximately €580,500 of the €3.87 million total.
Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has hailed a transformational year in its development of the Pitfield titanium project in Western Australia, with the coming 12 months set to focus on further de-risking the path to production.
The company's key achievement during the year was the completion of its maiden mineral resource estimate, which confirmed the deposit at 2.2 billion tonnes grading 5.1% titanium dioxide (TiO₂) – among the largest titanium resources globally.
Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL, VFEX:CMCL) reported a near-tripling of annual profit after a surging gold price drove revenue up 46% to $267.7 million in 2025.
The Zimbabwe-focused producer's total gold sales edged up to 79,075 ounces from 77,917 ounces, meaning the bulk of the earnings uplift came from price rather than volume, with the average realised gold price rising sharply against 2024 levels.
The consumer healthcare company's new Intense formula showed stronger early effects than its existing product in a 223-person study
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the Eroxon erectile dysfunction gel, has reported positive results from a home user trial of both its existing product and a new, stronger formulation called Eroxon Intense.
D3 Energy Ltd (ASX:D3E, OTCQX:DNRGF) has secured firm commitments to raise $6.12 million through a placement to institutional and sophisticated investors, with the money to advance drilling, development studies and exploration across its South African and Australian assets.
The company will issue 17,000,000 new shares at $0.36 each, with the placement attracting strong support from both new and existing investors. The capital raise marks D3 Energy’s first since listing in May 2024 and provides funding certainty to progress key growth initiatives.
Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF)'s ACCENT trial has reached an important milestone after an independent central review confirmed five complete responses in patients treated with narmafotinib alongside gemcitabine and Abraxane in first-line advanced pancreatic cancer.
The company said the updated result from the 64-patient Phase 1b/2a study represents a complete response rate of 7.8%, which it believes is unprecedented in this setting.
Cyprium Metals Ltd (ASX:CYM, OTCQB:CYPMF) has completed Tranche 2 of its two-tranche placement, finalising a broader capital raising that brought in about A$41 million before costs to support growth plans at the Nifty Copper Complex in Western Australia.
The copper developer, which is pursuing a phased restart of Nifty in the Paterson region, said it had issued 676,924 shares to company directors following shareholder approval on March 9, 2026.
Lindian Resources Ltd (ASX:LIN, OTC:LINIF) has marked a key step forward at its flagship Kangankunde rare earths project in Malawi, bringing its on-site accommodation camp online and enabling the next phase of construction and workforce mobilisation.
The Tipume accommodation camp is now operational, with initial units completed and occupied ahead of schedule, establishing a permanent on-site presence and removing a key logistical bottleneck as the project transitions into full execution.